Abstract
From the fresh fruiting bodies of the mushroom Pleurotus eryngii a phytase with a molecular mass of 14 kDa was isolated. The isolation protocol entailed ion exchange chromatography on DEAE-cellulose and CM-cellulose, affinity chromatography on Affi-gel blue gel, and ion exchange chromatography on Q-Sepharose. The phytase was unadsorbed on DEAE-cellulose, CM-cellulose and Affi-gel blue gel, and adsorbed on Q-Sepharose. It appeared as a single band in SDSPAGE. It exhibited maximal activity at around 37°C. Its activity underwent little changes over the range of pH 3.0 to 9.0. The aforementioned characteristics are different from those of animal, plant and bacterial phytases. The low molecular mass and pH stability of P. eryngii phytase also distinguish it from mushroom phytases and other fungal phytases reported earlier. The purified enzyme exhibited a broad substrate specificity on a range of phosphorylated compounds, and the phytase demonstrated the N-terminal sequence ADNVYRHDNN which shows little homology to known phytases. It inhibited proliferation of human nasopharyngeal carcinoma CNE2 cells, hepatoma HepG2 cells and breast cancer MCF7 cells with an IC50 of 1.9 µM, 2.9 µM, and 1.0 µM, respectively.
Keywords: Phytas isolation, Pleurotus eryngii, antiproliferative, fruiting bodies, mushroom, chromatography, fungal phytase, nasopharyngeal carcinoma, hepatoma
Protein & Peptide Letters
Title:Isolation of a Phytase with Distinctive Characteristics from an Edible Mushroom, Pleurotus eryngii
Volume: 20 Issue: 4
Author(s): Miao Li, Hexiang Wang and Tzi Bun Ng
Affiliation:
Keywords: Phytas isolation, Pleurotus eryngii, antiproliferative, fruiting bodies, mushroom, chromatography, fungal phytase, nasopharyngeal carcinoma, hepatoma
Abstract: From the fresh fruiting bodies of the mushroom Pleurotus eryngii a phytase with a molecular mass of 14 kDa was isolated. The isolation protocol entailed ion exchange chromatography on DEAE-cellulose and CM-cellulose, affinity chromatography on Affi-gel blue gel, and ion exchange chromatography on Q-Sepharose. The phytase was unadsorbed on DEAE-cellulose, CM-cellulose and Affi-gel blue gel, and adsorbed on Q-Sepharose. It appeared as a single band in SDSPAGE. It exhibited maximal activity at around 37°C. Its activity underwent little changes over the range of pH 3.0 to 9.0. The aforementioned characteristics are different from those of animal, plant and bacterial phytases. The low molecular mass and pH stability of P. eryngii phytase also distinguish it from mushroom phytases and other fungal phytases reported earlier. The purified enzyme exhibited a broad substrate specificity on a range of phosphorylated compounds, and the phytase demonstrated the N-terminal sequence ADNVYRHDNN which shows little homology to known phytases. It inhibited proliferation of human nasopharyngeal carcinoma CNE2 cells, hepatoma HepG2 cells and breast cancer MCF7 cells with an IC50 of 1.9 µM, 2.9 µM, and 1.0 µM, respectively.
Export Options
About this article
Cite this article as:
Li Miao, Wang Hexiang and Bun Ng Tzi, Isolation of a Phytase with Distinctive Characteristics from an Edible Mushroom, Pleurotus eryngii, Protein & Peptide Letters 2013; 20 (4) . https://dx.doi.org/10.2174/0929866511320040010
DOI https://dx.doi.org/10.2174/0929866511320040010 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Properties and Therapeutic Potential of Transient Receptor Potential Channels with Putative Roles in Adversity: Focus on TRPC5, TRPM2 and TRPA1
Current Drug Targets Editorial [Hot Topic: How Drugs may Work to Better Protect the Gastrointestinal Tract: Mechanisms Involved in Gastrointestinal Tract Protection]
Current Pharmaceutical Design Recurrent Left Atrial Low-grade Malignant Inflammatory Myofibroblastic Tumor Characterized by Cardiovascular Magnetic Resonance
Current Medical Imaging Drug Transporters and Multiple Drug Resistance in the Most Common Pediatric Solid Tumors
Current Drug Metabolism Local Gene Delivery for Cancer Therapy
Current Gene Therapy Comprehensive Analysis for Histone Acetylation of Human Colon Cancer Cells Treated with a novel HDAC Inhibitor
Current Pharmaceutical Design Recent Advances in Antabuse (Disulfiram): The Importance of its Metal-binding Ability to its Anticancer Activity
Current Medicinal Chemistry Recent Patents Related to Phosphorylation Signaling Pathway on Cancer
Recent Patents on DNA & Gene Sequences Blockade of Furin Activity and Furin-Induced Tumor Cells Malignant Phenotypes By The Chemically Synthesized Human Furin Prodomain
Current Medicinal Chemistry Thiazole Containing Nitrogen Mustards: Synthesis, Structural Evaluation, Cytotoxicity and DNA Binding Studies
Letters in Drug Design & Discovery Diagnosing and Treating Catatonia: An Update
Current Psychiatry Reviews Antibodies Against G-Protein Coupled Receptors: Novel Uses in Screening and Drug Development
Combinatorial Chemistry & High Throughput Screening Metal Complexes, their Cellular Targets and Potential for Cancer Therapy
Current Pharmaceutical Design Nutrigenomics: Advances, Opportunities and Challenges in Understanding the Nutrient-Gene Interactions
Current Nutrition & Food Science Electrochemically Driven Supramolecular Interaction of Quinones and Ferrocifens: An Example of Redox Activation of Bioactive Compounds
Current Topics in Medicinal Chemistry Substance P: Structure, Function, and Therapeutics
Current Topics in Medicinal Chemistry Virotherapy as An Approach Against Cancer Stem Cells
Current Gene Therapy 2-((1H-1,2,3-triazol-1-yl)methyl)-3-phenylquinazolin-4(3H)-ones: Design, Synthesis and Evaluation as Anti-cancer Agents
Current Bioactive Compounds New Indications for Established Drugs: Combined Tumor-Stroma-Targeted Cancer Therapy with PPARγ Agonists, COX-2 Inhibitors, mTOR Antagonists and Metronomic Chemotherapy
Current Cancer Drug Targets Advanced Assessment of the Endogenous Hormone Level as a Potential Biomarker of the Urogenital Tract Cancer
Combinatorial Chemistry & High Throughput Screening